logo-loader
viewVyome Therapeutics Inc.

Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Blackrock Gold brings on very experienced new Director while...

Blackrock Gold (CVE: BRC) CEO Andrew Pollard joined Steve Darling from Proactive Vancouver to discuss a number of things happening with the company including Blackrock adding a new member to their board of directors. Pollard talking about what he likes about David Laing. Pollard also telling...

26 minutes ago

2 min read